



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/814,555      | 03/30/2004  | Matthew D. Linnik    | 252312008000        | 7418             |

25226 7590 01/29/2008  
MORRISON & FOERSTER LLP  
755 PAGE MILL RD  
PALO ALTO, CA 94304-1018

|          |
|----------|
| EXAMINER |
|----------|

SAJJADI, FEREYDOUN GHOTB

|          |              |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

1633

|           |               |
|-----------|---------------|
| MAIL DATE | DELIVERY MODE |
|-----------|---------------|

01/29/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

|                          |                        |                     |  |
|--------------------------|------------------------|---------------------|--|
| <b>Interview Summary</b> | <b>Application No.</b> | <b>Applicant(s)</b> |  |
|                          | 10/814,555             | LINNIK ET AL.       |  |
|                          | <b>Examiner</b>        | <b>Art Unit</b>     |  |
|                          | Fereydoun G. Sajjadi   | 1633                |  |

All participants (applicant, applicant's representative, PTO personnel):

(1) Fereydoun G. Sajjadi.

(3) Matthew D. Linnik.

(2) Joseph Woitach.

(4) Catherine M. Polizzi/Alicia J. Hager.

Date of Interview: 23 January 2008.

Type: a) ☐ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☒ Yes e) ☐ No.

If Yes, brief description: Proposed claim amendments.

Claim(s) discussed: 1-6, 10-19 and 23-41.

Identification of prior art discussed: Wallace, D. (of record).


Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☒ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

  
Examiner's signature, if required

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Dr. Linnik presented an overview of the invention. Claim rejections under 35 USC 112 first and second paragraphs and 35 USC 102(b) were addressed. Specifically discussed issues raised in the final office action dated 11/14/2007, with respect to claim limitations, dosages, sustained reduction of antibody levels and their respective support in the specification. Additionally discussed proposed claim limitations to overcome the teachings of the prior art. Applicants indicated that they would consider filing a Rule 1.132 Declaration with respect to clinical data on LJP394 .